A Point-of-Care Interactive Decision Tool Reveals Variance Between Clinicians and Experts in Selecting Among GLP-1 RAs in T2D

Background: T2D management is shifting toward treating patients with therapies that align with their level of CV and end-organ risk. To this end, evidence-based guidelines now recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for both glycemic and extraglycemic benefits. The great spee...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Zachary, Mir-Hudgeons, Kiran, Roc, Anne, Zimmerman, Robert S, Peters, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089797/
http://dx.doi.org/10.1210/jendso/bvab048.949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089797/
http://dx.doi.org/10.1210/jendso/bvab048.949

Ejemplares similares